Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
In brief
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
Key facts
- Study ID
- NCT03829657
- Run by
- Theravance Biopharma
- People needed
- 203
- Starts
- 2019-02-22
- Expected to finish
- 2021-11-10
- Last updated by the study team
- 2023-01-20
Who can join
Age: 30 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UC San Diego Movement Disorder Center — La Jolla, California, United States
- Stanford Neuroscience Health Center — Palo Alto, California, United States
- Colorado Springs Neurological Associates, PC — Colorado Springs, Colorado, United States
- Parkinson's Disease and Movement Disorders Center — Boca Raton, Florida, United States
- SFM Clinical Research, LLC — Boca Raton, Florida, United States
- Neurostudies, Inc — Port Charlotte, Florida, United States
- Rush University Medical Center — Chicago, Illinois, United States
- NorthShore University Health System — Glenview, Illinois, United States
- University of Kansas Medical Center Research Institute, Inc. — Kansas City, Kansas, United States
- Mayo Clinic — Rochester, Minnesota, United States
- New York University Langone Health — New York, New York, United States
- Wake Forest University Baptist Health Sciences — Winston-Salem, North Carolina, United States
- University of Cincinnati Medical Center (UCGNI) — Cincinnati, Ohio, United States
- Ohio State University - Wexner Medical Center — Columbus, Ohio, United States
- Oregon Health & Science University — Portland, Oregon, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center — Dallas, Texas, United States
- Georgetown University Hospital — McLean, Virginia, United States
- Inland Northwest Research — Spokane, Washington, United States
- Concord Hospital, Neurosciences Department — Concord, New South Wales, Australia
- Clinical Trials Centre, Level 3 Monash Health Translational Precinct Building Monash Medical Centre — Clayton, Victoria, Australia
- The Royal Melbourne Hospital Neurology Department — Parkville, Victoria, Australia
- Perron Institute for Neurological and Translational Science — Nedlands, Western Australia, Australia
- Medizinische Universitat Innsbruck, Abteilung fur Neurologie — Innsbruck, Austria
- Banner Sun Health Research Institute — Sun City, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.